# Pharvaris Announces Annual General Meeting of Shareholders
Canonical URL: https://biopharmsignal.com/news/PHVS/pharvaris-announces-annual-general-meeting-of-shareholders-d8f6d597
Ticker: PHVS
Company: Pharvaris
Source: Pharvaris
Published: 2026-06-11 10:50 EST
## Summary

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2...

## Article Body
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the annual general meeting of shareholders will take place on Friday, June 26, 2026, at 16:00 CEST (10:00 a.m. EDT).

All relevant documents and information relating to the annual general meeting, including the notice and agenda for the annual general meeting, are or will be made available in the “Investors” section of Pharvaris’ website under “Events & Presentations”. The documents will also be made available on the SEC’s website at www.sec.gov. Shareholders who wish to attend the meeting should register as described in the notice and agenda for the annual general meeting.

About Pharvaris Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. Pharvaris is preparing marketing authorization applications for deucrictibant immediate-release capsule as an on-demand treatment of HAE attacks, and a global pivotal Phase 3 study of deucrictibant extended-release tablet for the prevention of HAE attacks (CHAPTER-3) is ongoing with topline data anticipated in the third quarter of 2026. In addition, CREAATE is an ongoing Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks. For more information, visit https://pharvaris.com/ .
## Recent Company News
- 2026-07-22 10:50 EST — [Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema](https://biopharmsignal.com/news/PHVS/publication-in-clinical-reviews-in-allergy-immunology-summarizes-decades-of-evid-a202e0d7) — Source: Pharvaris
- 2026-07-06 10:50 EST — [Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks](https://biopharmsignal.com/news/PHVS/pharvaris-announces-fda-acceptance-of-new-drug-application-for-deucrictibant-ir--11e9782b) — Source: Pharvaris
- 2026-06-15 10:50 EST — [Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026](https://biopharmsignal.com/news/PHVS/data-supporting-differentiated-profile-of-deucrictibant-in-hae-management-presen-1a36672e) — Source: Pharvaris
- 2026-06-11 10:50 EST — [Pharvaris Announces Annual General Meeting of Shareholders](https://biopharmsignal.com/news/PHVS/pharvaris-announces-annual-general-meeting-of-shareholders-d8f6d597) — Source: Pharvaris
- 2026-05-29 10:50 EST — [Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026](https://biopharmsignal.com/news/PHVS/pharvaris-to-present-clinical-data-at-the-eaaci-annual-congress-2026-f5146f6d) — Source: Pharvaris
## Related News
- 2026-07-28 20:15 EST — BDX — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a)
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)